SAGE Therapeutics Inc (NASDAQ:SAGE) – Stock analysts at SunTrust Banks lifted their Q1 2019 earnings per share (EPS) estimates for shares of SAGE Therapeutics in a report issued on Tuesday, February 19th. SunTrust Banks analyst J. Lee now forecasts that the biopharmaceutical company will earn ($2.66) per share for the quarter, up from their prior forecast of ($2.83). SunTrust Banks also issued estimates for SAGE Therapeutics’ Q2 2019 earnings at ($2.79) EPS, Q3 2019 earnings at ($2.81) EPS, Q4 2019 earnings at ($2.94) EPS, FY2019 earnings at ($10.89) EPS, FY2020 earnings at ($9.74) EPS, FY2021 earnings at ($5.19) EPS, FY2022 earnings at $1.33 EPS and FY2023 earnings at $12.84 EPS.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($3.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.89) by ($0.49). The business had revenue of $0.27 million for the quarter. During the same quarter in the prior year, the company posted ($1.75) EPS.
Several other analysts have also recently commented on SAGE. Guggenheim assumed coverage on shares of SAGE Therapeutics in a research note on Friday. They issued a “buy” rating and a $205.00 target price for the company. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. Wolfe Research assumed coverage on shares of SAGE Therapeutics in a research note on Friday, December 14th. They issued an “outperform” rating for the company. ValuEngine cut shares of SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, JPMorgan Chase & Co. set a $205.00 target price on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $201.58.
SAGE stock opened at $153.97 on Friday. SAGE Therapeutics has a one year low of $79.88 and a one year high of $188.82. The firm has a market capitalization of $6.88 billion, a PE ratio of -19.06 and a beta of 2.93.
In related news, Director James M. Frates sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $134.81, for a total value of $1,011,075.00. Following the completion of the sale, the director now owns 11,735 shares in the company, valued at $1,581,995.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven M. Paul sold 1,543 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $161.62, for a total transaction of $249,379.66. Following the completion of the sale, the director now owns 272,777 shares of the company’s stock, valued at approximately $44,086,218.74. The disclosure for this sale can be found here. Insiders sold a total of 81,452 shares of company stock valued at $12,666,865 in the last 90 days. Company insiders own 5.10% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtus ETF Advisers LLC lifted its stake in shares of SAGE Therapeutics by 2.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,948 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 77 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of SAGE Therapeutics by 34.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 310 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 80 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of SAGE Therapeutics by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,676 shares of the biopharmaceutical company’s stock valued at $831,000 after purchasing an additional 239 shares during the period. Principal Financial Group Inc. lifted its stake in shares of SAGE Therapeutics by 1.1% in the fourth quarter. Principal Financial Group Inc. now owns 23,202 shares of the biopharmaceutical company’s stock valued at $2,222,000 after purchasing an additional 243 shares during the period. Finally, Benjamin F. Edwards & Company Inc. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at about $29,000.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).